Sugi Predict

Sugi Predict / Compounds / SCHEMBL10176850

SCHEMBL10176850

SCHEMBL10176850

CC(C)Cc1ccc2c(c1)OCCN2C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 1/20 0.47
▸ CYP11B1 P15538 1/20 0.46
▸ CYP11B2 P19099 1/20 0.46
▸ NOTUM Q6P988 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ LMNA P02545 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ KDM5B Q9UGL1 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ PRMT5 O14744 1/20 0.39
▸ WDR77 Q9BQA1 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ TAAR1 Q96RJ0 2/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ PTGES2 Q9H7Z7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176854 0.89 RORC (0.46) CYP11B1CYP11B2ALDH1A1LMNATHRB
SCHEMBL24401238 0.84 PRMT5 (0.39) PDE10AALDH1A1PRMT5WDR77RORC
SCHEMBL2633106 0.83 PDE10A (0.50) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL18656448 0.81 PDE10A (0.49) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL22984287 0.81 PDE10A (0.45) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL24866255 0.80 PDE10A (0.48) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL19225688 0.79 PDE10A (0.47) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL31061893 0.79 TAAR1 (0.49) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL12265339 0.79 PDE10A (0.50) PDE10ACYP11B1CYP11B2NOTUMALDH1A1
SCHEMBL70633 0.76 TDP1 (0.53) PDE10ACYP11B1CYP11B2NOTUMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49080-E1 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2022-05-24 — — US disclosed
US-10975093-B2 Fused 1,4-diazepines as BET protein degraders THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-04-13 — — US disclosed
US-20210002289-A1 MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION UNIV MICHIGAN REGENTS (US) 2021-01-07 — — US disclosed
US-20190263827-A1 FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2019-08-29 — — US disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20150141354-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 — — US disclosed
US-20140274921-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-8828951-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2014-09-09 — — US disclosed
US-8466114-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2013-06-18 — — US disclosed
US-8394772-B2 Glycoside derivative and uses thereof NOVARTIS AG (CH) 2013-03-12 — — US disclosed
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2013-01-17 — — US disclosed
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2013-01-17 — — US disclosed
US-20120196813-A1 GLYCOSIDE DERIVATIVE AND USES THEREOF NOVARTIS AG (CH) 2012-08-02 — — US disclosed
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2012-07-12 — — US disclosed
US-8163704-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2012-04-24 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PDE10A 863/4885CYP11B1 311/4885CYP11B2 316/4885
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PDE10A 863/4885CYP11B1 311/4885CYP11B2 316/4885
US-20190263827-A1 FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS BRD4, BRD1, BET1 PDE10A 4439/4885CYP11B1 3820/4885CYP11B2 4285/4885
US-20150141354-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PDE10A 863/4885CYP11B1 311/4885CYP11B2 316/4885
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PDE10A 863/4885CYP11B1 311/4885CYP11B2 316/4885
US-10975093-B2 Fused 1,4-diazepines as BET protein degraders BRD4, BRD1, BET1 PDE10A 4439/4885CYP11B1 3820/4885CYP11B2 4285/4885
US-20110171159-A1 Glycoside Derivatives and Uses Thereof SLC5A1, SLC5A2, SLC2A1 PDE10A 863/4885CYP11B1 311/4885CYP11B2 316/4885
US-20210002289-A1 MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION MDM2, CD74, TNFSF10 PDE10A 4635/4885CYP11B1 3728/4885CYP11B2 3927/4885
US-20140274921-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PDE10A 863/4885CYP11B1 311/4885CYP11B2 316/4885
US-20120196813-A1 GLYCOSIDE DERIVATIVE AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PDE10A 957/4885CYP11B1 311/4885CYP11B2 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.